Form 4: Cartesian Therapeutics Executive Emily English Reports Stock and Option Awards

Emily English, Chief Operations Officer of Cartesian Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• Emily English, the Chief Operations Officer of Cartesian Therapeutics, filed a Form 4 detailing changes in her beneficial ownership of the company's securities.
• On January 2, 2025, she acquired 16,100 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 47,400 shares of common stock.
• The RSUs vest as to 25% on January 2, 2026, with the remaining shares vesting in three equal annual installments, fully vesting on January 2, 2029.
• The stock options also vest as to 25% on January 2, 2026, with the remaining shares vesting in three equal annual installments, fully vesting on January 2, 2029, and expire on January 1, 2035.
• Following these transactions, English directly owns 42,023 shares of common stock and holds options for 47,400 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future. The vesting schedule suggests a long-term commitment from the COO, which is generally viewed positively.

Positives

• The grant of RSUs and stock options to the COO aligns her interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedule of both the RSUs and stock options encourages continued service and commitment from the COO over the next four years.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the equity awards suggests a multi-year commitment from the COO.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract and retain key executives. The specific terms of the awards (vesting schedule, exercise price) are tailored to the company's stage of development and strategic goals.

Comparison to Industry Standards

• Equity grants to C-level executives in biotech companies are standard practice.
• Vesting schedules of 3-4 years are typical to ensure long-term alignment.
• Exercise prices for options are usually set at or above the current market price at the time of grant.
• Comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize similar equity compensation packages for their executives.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the equity grants as a sign of the company's commitment to its leadership team.

Key Dates